ADVERTORIAL
THE FUTURE OF CARDIAC HEALTH:
New Imaging Technology Marks Major Shift In the Diagnosis and Treatment Of Heart Disease
A novel micro-cap medical device company is pioneering a new type of cardiac imaging technology that could revolutionize the treatment of heart disease.
The company’s compact, portable imaging system generates complete, highly-accurate 3D models of the heart from standard 2D echocardiogram images.
These models provide doctors with accurate measurements of crucial diagnostic metrics, such as volume and ejection fraction calculations.
This means many patients can bypass the expensive, difficult, often uncomfortable experience of having Magnetic Resonance Imaging (MRI) scans.
Instead of cardiac patients being thrust into a dark metal tube with deafening clanging sounds for upwards of two hours, as is common with room-sized MRI machines in hospitals, the VMS technology utilizes the same small, hand-held ultrasound probe used for pregnant women.
In other words, this companies less-invasive, less expensive, patient-friendly technology could revolutionize the diagnosis of heart disease for many patients.
It’s estimated that tens of millions of heart patients worldwide are not getting the regular cardiac diagnostics they should because of the difficulty and expense of booking MRI scans.
Plus, this company has partnered with one of the largest medical device companies in the world, GE Healthcare, to offer its potentially life-saving technology for use with the 1.2 million ultrasound units worldwide.
Providing Critical Diagnostics When Cardiac Patients Need Them Most
One of the little-known secrets about the diagnosis and treatment of heart disease is just how difficult it is for cardiologists to get accurate information about the condition of their patients’ hearts.
The technology to get such information exists – but it’s hugely expensive and much scarcer than many people realize.
In the U.S. alone, an estimated 20 million people suffer from heart disease with another 2.4 million, including 1.4 million small children, suffering from congenital heart defects (CHD).1 Guidelines from cardiology experts state that these patients should be checked with diagnostic imaging every three to six months.
Yet at present, the only way to get complete and accurate information is with the high-resolution 3D images produced by Magnetic Resonance Imaging or MRI scans – a time-consuming, laborious procedure that is usually fully booked.
The powerful, room-sized MRI machines cost between $3 to $5 million each and must be housed in special hospital wings (usually custom-built for $20 million) built without any of the metal found in standard reinforced concrete.
What’s more, many heart patients can’t have MRI scans done on them due to presence of metallic devices, such as stents or pacemakers, in their bodies.
And it’s estimated that only 40 percent of heart patients will even submit to or are capable of getting the scans – of which up to 25 percent of those are unable to finish the entire two-hour procedure, rendering the scans useless.
Worst of all, the economics of operating MRI machines means that openings for cardiac MRI screenings are rare because radiologists can scan up to ten cancer patients (15 to 20 minutes each) in the time it takes to scan one cardiac patient.
A Fast, Low-Cost, Accurate Alternative for MRI Scans
The technology is a relatively inexpensive (around $50,000) “add-on” device that works with most ultrasound scanners.
Yet with its proprietary and revolutionary Artificial Intelligence (AI) technology, it can generate accurate 3D models of the heart from ordinary ultrasound scans — and provide cardiologists with most of the crucial information they get from MRI machines.
This means that doctors can perform routine cardiac diagnostics in their own offices rather than having to wait months, even years for an opening at a hospital’s MRI unit.
That’s how this company could revolutionize the practice of cardiology – and potentially be a game-changer for millions..
No Competition in a Rapidly Growing Global Market
The best thing for investors is that it has pioneered a brand-new type of imaging system – and therefore has no direct competitors.
Big medical device conglomerates have tried for years to develop 3D ultrasound scanners to compete with MRI machines but have yet to succeed.
There are technical reasons why this is so, but the simple explanation is that a heart moves too quickly to be captured in a 3D holographic image. For this reason, doctors have had no choice but to rely on the only other existing imaging technology, MRI machines.
That is, until now.
In the U.S. alone, an estimated 20 million people over age 20 have coronary artery disease (CAD), and each year about 805,000 people are struck down by a heart attack.
Plus, another 2.4 million suffer from congenital heart defects, such as heart valve defects, that should be checked regularly.
To serve the needs of patients in the U.S., Canada and Europe, the company estimates at least 50,000 of its VMS units would be needed.
At approximately $50,000 cost per unit, that represents potential future revenues of some $2.5 billion.
Once sales of the units begin in 2023, this company’s revenues could potentially skyrocket.
And with the price of medical device stocks soaring as demand for advanced diagnostic services increases every year, small medical diagnostic companies often offer an attractive risk-to-reward ratios.
8 Excellent Reasons to Consider This Companies for Your Speculative Portfolio
- Reason #1: Growing Market. The medical device market is expanding despite a mediocre economy, projected to grow from $495.4 billion in 2022 to $718.9 billion by 2029.2
- Reason #2: Breakthrough New Technology this companies new imaging technology is so new and exciting that some of the largest medical device companies in the world, such as GE Healthcare, have already made distribution deals with the company!
- Reason #3: No Competition. With the average cost of a new MRI machine hovering around $5 million and $20 million for the hospital wing, cardiologists worldwide are desperate for this companies low-cost, easily-available solutions. Yet this companies 3D imaging technology is, for now, the only ultrasound 3D imaging solution for the heart currently on the market.
- Reason #4: Endorsed by Experts Worldwide. Leading cardiologists and experts at diagnostic imaging have endorsed this companies technology, for example saying that this medical system will enable us to better image the hearts of patients at risk for pulmonary hypertension and is a wonderful alternative to MRI.”
- Reason #5: Immediate Customers. This companies imaging system can be used with most existing ultrasound devices, giving the company access to millions of customers almost immediately.
- Reason #6: Dream Team. The team behind this companies is impressive, with serial entrepreneur and Chairman of the Board Dr. George Adams having a proven track record with 10 startup companies and as a director of 10 venture capital funds
- Reason #7: Huge Opportunity for Investors. Despite the enormous global market and potential for this technology, this companies has just begun shipping its 3D imaging devices. As a result, it’s still possible to pick up shares of the company for less than $1 per share. No guarantees, but a modest initial investment could potentially reap substantial rewords in the event of a buy-out or merger.
- Reason #8: Making a Difference. Investors invest to make money. But it’s not very often that you can potentially make money while also contributing to a significant medical advance This companies breakthrough technology could be such an advance, and risking a few hundred or few thousand dollars on its chances could make a real difference.
It appears there is nothing but upside for the rapidly growing company that still trades at a price well below its peers.
But it won’t for long. As more news is generated and word gets out, expect investors to discover this next-generation diagnostics solution.
Sign up with your email address to learn more about this fast-growing opportunity.
Legal Notice: This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any company or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
